<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524510</url>
  </required_header>
  <id_info>
    <org_study_id>PML_DOC_1101</org_study_id>
    <nct_id>NCT01524510</nct_id>
  </id_info>
  <brief_title>Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients</brief_title>
  <official_title>Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this open prospective study 40 patients who received Mandibular Replacement Appliance&#xD;
      (MRA) Therapy as treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) will be&#xD;
      included. The patient's sleep will be registered during 2 periods of 2 days: one while the&#xD;
      patient does not wear the MRA and, +/- 1 week later, one while the patient wears the MRA.&#xD;
      Furthermore, 2 low dose CT scans (one with and one without the MRA device in the mouth) will&#xD;
      be taken. These data must allow the investigators to validate the use of functional imaging&#xD;
      (segmentation and Computational Fluid Dynamics) as a predictor of the outcome of the MRA&#xD;
      therapy in OSAHS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in mean AHI between visit 1 and visit 2</measure>
    <time_frame>visit 1 (AHI of 2 nights without MRA) / visit 2 (AHI of 2 nights with MRA) (visit 2 happens +/- 1 week after visit 1)</time_frame>
    <description>evaluate the predictive value of upper airway segmentation and CFD analysis on responsiveness to MRA therapy in OSAHS patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in UA resistance</measure>
    <time_frame>1 CT scan without MRA (UA resistance without MRA) / 1 CT scan with MRA (UA resistance with MRA)</time_frame>
    <description>evaluate the predictive value of upper airway segmentation and CFD analysis on responsiveness to MRA therapy in OSAHS patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in mean ESS between visit 1 and visit 2</measure>
    <time_frame>visit 1 (ESS of 2 nights without MRA) / visit 2 (ESS of 2 nights with MRA) (visit 2 happens +/- 1 week after visit 1)</time_frame>
    <description>to assess the effect of the MRA therapy on daytime sleepiness with the Epworth Sleepiness Scale (ESS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>MRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>low dose radiation scan without contrast without and with MRA</description>
    <arm_group_label>MRA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alice PDx polygraphy</intervention_name>
    <description>Alice PDx polygraphy (Respironics)</description>
    <arm_group_label>MRA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with documented OSAHS based on the following criteria:&#xD;
&#xD;
             AHI &gt;= 5 Complaints of extreme daytime sleepiness with no other explanation and/or 2&#xD;
             or more of the following symptoms:&#xD;
&#xD;
               -  choking or gasping during sleep&#xD;
&#xD;
               -  recurrent awakenings from sleep&#xD;
&#xD;
               -  un-refreshing sleep&#xD;
&#xD;
               -  daytime fatigue&#xD;
&#xD;
               -  impaired concentration&#xD;
&#xD;
          2. Patients who received MRA as treatment for OSAHS&#xD;
&#xD;
          3. AHI &gt;= 5 on at least 1 of the screening nights (patient does not wear MRA device)&#xD;
&#xD;
          4. Male or female patients aged â‰¥ 18 years&#xD;
&#xD;
          5. Patients with a co-operative attitude&#xD;
&#xD;
          6. Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating females or females at risk of pregnancy&#xD;
&#xD;
          2. Patients with an uncontrolled disease or any condition that might, in the judgement of&#xD;
             the investigator, place the patient at undue risk or potentially compromise the&#xD;
             results or interpretation of the study.&#xD;
&#xD;
          3. Cancer or any other chronic disease with poor prognosis and/or affecting patient&#xD;
             status&#xD;
&#xD;
          4. History of alcohol or drug abuse in the last 2 years&#xD;
&#xD;
          5. Patients unlikely to comply with the protocol or unable to understand the nature,&#xD;
             scope and possible consequences of the study&#xD;
&#xD;
          6. Patients who participate in another clinical study whose investigational plan is&#xD;
             judged to interfere or affect any of the measures of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wilfried De Backer, MD</last_name>
    <phone>+32 3 821 3447</phone>
    <email>wilfried.de.backer@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemie Hufkens, MSc</last_name>
    <phone>+32 3 821 41 42</phone>
    <email>annemie.hufkens@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried De Backer, MD</last_name>
      <phone>+32 3 821 34 47</phone>
      <email>wilfried.de.backer@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Annemie Hufkens, MSc</last_name>
      <phone>+32 3 821 41 42</phone>
      <email>annemie.hufkens@uza.be</email>
    </contact_backup>
    <investigator>
      <last_name>Wilfried De Backer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Wilfried De Backer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>OSAS</keyword>
  <keyword>AHI</keyword>
  <keyword>MRA</keyword>
  <keyword>CFD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

